This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vaccine for Lung Cancer

GlaxoSmithKline plc

Drug Names(s): Ad/L523S

Deal Structure: During May and June 1999, Corixa entered into corporate partnerships with Zambon and JT, respectively, for the research, development and commercialization of vaccine products aimed at preventing and/or treating lung cancer. Zambon has exclusive rights to develop and sell vaccine products in Europe, the former countries of the Soviet Union, Argentina, Brazil and Columbia and co-exclusive rights in China. Under the June 1999 agreement, Corixa granted JT exclusive rights to develop and sell vaccine products outside of the territory licensed to Zambon, including the United States and Japan, and co-exclusive rights to develop and sell vaccine products in China. Corixa also granted Zambon a nonexclusive license and JT an option to formulate vaccines that may result from the collaboration using Corixa's microsphere delivery system with Corixa's proprietary adjuvants.

During 2002, the 3-year research terms of the agreements expired and the respective research funding obligations ceased....See full deal structure in Biomedtracker

Vaccine for Lung Cancer News

Pink Sheet New EU Approvals

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug